This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:2085.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved capecitabine (Xeloda, Hoffman LaRoche Inc, Nutley, NJ) combined with docetaxel (Taxotere, Aventis Pharmaceuticals, Parsippany, NJ) for treating patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

The combination therapy was approved on the basis of an open-label randomized trial in 75 centers worldwide. Participants were 511 patients with metastatic breast cancer resistant to or recurring or relapsing during or after anthracycline-containing therapy. In the combination arm, 225 patients were randomized to receive Xeloda, 1250 mg/m² twice daily for 14 days followed by 1 week without treatment, and Taxotere, 75 mg/m² as a 1-hour intravenous infusion, given in 3-week cycles. In the monotherapy arm, 256 patients received Taxotere, 100 mg/m² as a 1-hour intravenous infusion, administered in 3-week cycles. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. The combination therapy resulted in significant improvement . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
Malet-Martino and Martino
The Oncologist 2002;7:288-323.
ABSTRACT | FULL TEXT